IMNM Stock Risk & Deep Value Analysis

Immunome demonstrates strong 10x potential, primarily driven by the strategic acquisition of late-stage oncology assets, AL102 and AL101, significantly accelerating its path to market and revenue. This move diversifies its pipeline beyond its proprietary antibody discovery platform. Key catalysts include AL102's Phase 3 data and potential NDA filing for Desmoid Tumors within 12-24 months. The company has a solid cash runway and adaptable leadership. However, inherent biotech risks like clinical trial failure, future dilution, and intense competition remain. It avoids 'dud' status due to differentiated assets and a clear, executable vision for growth.